Back to Resource Library
Join us as we hear from two Korean companies working to bring NK cell-based therapies to market. Both CAR-modified NK cells to treat malignant and recurrent blood cancers as well as combination therapy of NK cells and local immunogenic chemotherapy to treat hepatocellular carcinoma will be discussed. Don’t miss this opportunity to stay up to date in NK Cell therapy with a specific focus on the Asia market.
© 2021 ISCT. All rights reserved.
Site by eConverse Media